{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:35:43Z","timestamp":1790307343786,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Abbvie,"},{"DOI":"10.13039\/100005564","name":"Gilead,","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ViiV,"},{"name":"Janssen,"},{"name":"Merck and"},{"name":"Theratechnologies,"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jgar.2019.08.010","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T12:02:02Z","timestamp":1566475322000},"page":"228-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-na\u00efve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety"],"prefix":"10.1016","volume":"20","author":[{"given":"Valeria","family":"Cento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2019.08.010_bib0005","series-title":"Linee Guida Italiane sull\u2019utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1. Edizione","author":"Societ\u00e0 Italiana di Malattie Infettive e Tropicali (SIMIT)","year":"2017"},{"key":"10.1016\/j.jgar.2019.08.010_bib0010","first-page":"247","article-title":"Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons","volume":"41","author":"Antinori","year":"2018","journal-title":"New Microbiol"},{"key":"10.1016\/j.jgar.2019.08.010_bib0015","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Last updated October 25, 2018; last reviewed October 25, 2018. US Department of Health and Human Services (DHHS). https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf."},{"key":"10.1016\/j.jgar.2019.08.010_bib0020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society\u2013USA Panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2019.08.010_bib0025","series-title":"EACS guidelines version 9.1","author":"European AIDS Clinical Society (EACS)","year":"2018"},{"key":"10.1016\/j.jgar.2019.08.010_bib0030","author":"GeSIDA","year":"2018"},{"key":"10.1016\/j.jgar.2019.08.010_bib0035","series-title":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance","author":"World Health Organization (WHO)","year":"2018"},{"key":"10.1016\/j.jgar.2019.08.010_bib0040","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199810293391801","article-title":"Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team","volume":"339","author":"Havlir","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2019.08.010_bib0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/jtbi.1997.0622","article-title":"Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads","volume":"192","author":"Wein","year":"1998","journal-title":"J Theor Biol"},{"key":"10.1016\/j.jgar.2019.08.010_bib0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-4690-10-22","article-title":"Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure","volume":"10","author":"Mespl\u00e8de","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.jgar.2019.08.010_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077448","article-title":"Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics","volume":"8","author":"DeAnda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2019.08.010_bib0060","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1128\/AAC.00157-11","article-title":"Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes","volume":"55","author":"Hightower","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.08.010_bib0065","first-page":"56","article-title":"Genetic barrier to resistance for dolutegravir","volume":"17","author":"Llibre","year":"2015","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jgar.2019.08.010_bib0070","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1124\/mol.111.073189","article-title":"Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S\/GSK1349572)","volume":"80","author":"Hare","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jgar.2019.08.010_bib0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/QAI.0000000000000966","article-title":"NRTI sparing therapy in virologically controlled HIV-1 infected subjects: results of a controlled, randomized trial (Probe)","volume":"72","author":"Maggiolo","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2019.08.010_bib0080","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/jac\/dky123","article-title":"Atazanavir\/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial","volume":"73","author":"Fabbiani","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.08.010_bib0085","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkw379","volume":"72","author":"Perez-Molina","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.08.010_bib0090","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","volume":"65","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.08.010_bib0095","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/QAI.0000000000000904","article-title":"Brief report: switch to ritonavir-boosted atazanavir plus raltegravir in virologically suppressed patients with HIV-1 infection: a randomized pilot study","volume":"71","author":"van Lunzen","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2019.08.010_bib0100","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1473-3099(14)70736-4","volume":"14","author":"Cahn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2019.08.010_bib0105","series-title":"25th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"DRV\/r\/3TC FDC for HIV-1 treatment-na\u00efve patients: week 48 results of the ANDES study","author":"Figueroa","year":"2018"},{"key":"10.1016\/j.jgar.2019.08.010_bib0110","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/jac\/dky566","article-title":"Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting","volume":"74","author":"d\u2019Arminio Monforte","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.08.010_bib0115","series-title":"11th Italian Conference on AIDS and Retroviruses (ICAR)","article-title":"Use of integrase-inhibitors as part of dual or triple regimens in the Italian MaSTER cohort between 2009 and 2017","author":"Iannuzzi","year":"2019"},{"key":"10.1016\/j.jgar.2019.08.010_bib0120","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/QAD.0000000000001845","article-title":"The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?","volume":"32","author":"Vitoria","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2019.08.010_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.12.052","article-title":"Integrase inhibitors in late pregnancy and rapid HIV viral load reduction","volume":"214","author":"Rahangdale","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jgar.2019.08.010_bib0130","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2019.08.010_bib0135","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/COH.0000000000000445","article-title":"Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials","volume":"13","author":"Hill","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jgar.2019.08.010_bib0140","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2019.08.010_bib0145","series-title":"10th IAS Conference on HIV Science","article-title":"Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-na\u00efve adults with HIV-1 infection\u201496-week results from the GEMINI studies","author":"Cahn","year":"2019"},{"key":"10.1016\/j.jgar.2019.08.010_bib0150","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2019.08.010_bib0155","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.08.010_bib0160","series-title":"10th IAS Conference on HIV Science","article-title":"Switching to DTG\/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO study)","author":"Van Wyk","year":"2019"},{"key":"10.1016\/j.jgar.2019.08.010_bib0165","series-title":"25th Annual Conference of the British HIV Association (BHIVA)","article-title":"Durable suppression and low rate of virologic failure 3 years after switch to DTG + RPV 2-drug regimen: SWORD-1 and -2 studies","author":"van Wyk","year":"2019"},{"key":"10.1016\/j.jgar.2019.08.010_bib0170","series-title":"26th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"HIV replication at <40c\/mL for DTG + 3TC vs DTG + TDF\/FTC in the GEMINI-1 & -2 studies","author":"Underwood","year":"2019"},{"key":"10.1016\/j.jgar.2019.08.010_bib0175","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/jac\/dkz190","article-title":"Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy","volume":"74","author":"Gillman","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.08.010_bib0180","article-title":"Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate\/emtricitabine: pooled results from the GEMINI studies","author":"Eron","year":"2018","journal-title":"HIV DART and Emerging Viruses"},{"key":"10.1016\/j.jgar.2019.08.010_bib0185","series-title":"10th IAS Conference on HIV Science","article-title":"Dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir\/emtricitabine (TDF\/FTC) fixed-dose combination in the GEMINI studies\u2014viral load rebound including \u2018blips\u2019 through 48 weeks","author":"Underwood","year":"2019"},{"key":"10.1016\/j.jgar.2019.08.010_bib0190","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1016\/S2352-3018(17)30183-2","article-title":"U=U taking off in 2017","volume":"4","author":"The Lancet HIV","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2019.08.010_bib0195","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1128\/AAC.00076-14","article-title":"Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients","volume":"58","author":"Ryscavage","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.08.010_bib0200","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/QAD.0b013e32834bbaa9","article-title":"Efficacy of a nucleoside-sparing regimen of darunavir\/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)","volume":"25","author":"Taiwo","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2019.08.010_bib0205","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2019.08.010_bib0210","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2019.08.010_bib0215","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and Week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2019.08.010_bib0220","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2019.08.010_bib0225","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2019.08.010_bib0230","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/cid\/cix1083","article-title":"ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA <500000 copies\/mL","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.08.010_bib0235","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1097\/QAD.0000000000002285","article-title":"Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients","volume":"33","author":"Radford","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2019.08.010_bib0240","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/civ981","article-title":"The cost-effectiveness and budget impact of 2-drug dolutegravir\u2013lamivudine regimens for the treatment of HIV infection in the United States","volume":"62","author":"Girouard","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.08.010_bib0245","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jac\/dkv430","article-title":"Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients","volume":"71","author":"Gubavu","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.08.010_bib0250","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2019.08.010_bib0255","series-title":"24th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Promising results of dolutegravir + lamivudine maintenance in ANRS 167 LAMIDOL trial","author":"Joly","year":"2017"},{"key":"10.1016\/j.jgar.2019.08.010_bib0260","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/S2352-3018(16)30015-7","article-title":"Efficacy and safety of contemporary dual\u2013drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis","volume":"3","author":"Achhra","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2019.08.010_bib0265","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12688\/f1000research.15995.1","article-title":"Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: systematic review and meta-analysis","volume":"7","author":"Wandeler","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.jgar.2019.08.010_bib0270","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir\u2013rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2019.08.010_bib0275","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/hiv.12506","article-title":"Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study","volume":"18","author":"Gantner","year":"2017","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2019.08.010_bib0280","doi-asserted-by":"crossref","DOI":"10.1177\/2325958218760847","article-title":"Safety and efficacy of dolutegravir plus rilpivirine in treatment-experienced HIV-infected patients: the DORIVIR study","volume":"17","author":"Palacios","year":"2018","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.jgar.2019.08.010_bib0285","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/1060028018761600","article-title":"Dolutegravir plus rilpivirine as a switch option in cART-experienced patients: 96-week data","volume":"52","author":"Capetti","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jgar.2019.08.010_bib0290","series-title":"9th IAS Conference on HIV Science","article-title":"Dual regimen with dolutegravir and lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance DOLULAM study","author":"Reynes","year":"2017"},{"key":"10.1016\/j.jgar.2019.08.010_bib0295","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3851\/IMP3270","article-title":"A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients","volume":"24","author":"Ciccullo","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2019.08.010_bib0300","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/23744235.2018.1554909","article-title":"Is HIV-1 viraemia below 20 copies\/mL in antiretroviral-treated patients associated with virologic outcome?","volume":"51","author":"den Oudsten","year":"2019","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.jgar.2019.08.010_bib0305","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0b013e3182567a57","article-title":"Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure","volume":"60","author":"Maggiolo","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2019.08.010_bib0310","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/cid\/cir936","article-title":"Plasma HIV-1 RNA detection below 50 copies\/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy","volume":"54","author":"Doyle","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.08.010_bib0315","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1038\/s41467-019-10884-9","article-title":"Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART","volume":"10","author":"Bachmann","year":"2019","journal-title":"Nat Commun"},{"issue":"Suppl. 8","key":"10.1016\/j.jgar.2019.08.010_bib0320","article-title":"Comparison of viral replication below 50 copies\/mL for 2-drug (DTG+RPV) vs 3-drug current antiretroviral regimen (CAR) therapy in the SWORD-1 and SWORD-2 studies. In: HIV Drug Therapy Glasgow 2018; 28\u201331 October 2019; Glasgow, UK","volume":"21","author":"Underwood","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jgar.2019.08.010_bib0325","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz056","article-title":"No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial","volume":"6","author":"Li","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2019.08.010_bib0330","series-title":"11th Italian Conference on AIDS and Retroviruses (ICAR)","article-title":"Residual viremia in HIV-infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide: a randomized study (Be-One Study \u2014 NCT03493568)","author":"Gianotti","year":"2019"},{"key":"10.1016\/j.jgar.2019.08.010_bib0335","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-med-042909-093756","article-title":"HIV infection, inflammation, immunosenescence, and aging","volume":"62","author":"Deeks","year":"2011","journal-title":"Annu Rev Med"},{"issue":"Suppl. 8","key":"10.1016\/j.jgar.2019.08.010_bib0340","article-title":"Dolutegravir + lamivudine dual therapy in patients with suppressed HIV-RNA: long term virological and immunological results of a multicentre cohort. In: HIV Drug Therapy Glasgow 2018; 28\u201331 October 2019; Glasgow, UK","volume":"21","author":"Maggiolo","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"Suppl. 8","key":"10.1016\/j.jgar.2019.08.010_bib0345","article-title":"Soluble activation and inflammation markers in HIV dual therapy in the setting of virological suppression: Trilobithe study. HIV Drug Therapy Glasgow 2018; 28\u201331 October 2019; Glasgow, UK","volume":"21","author":"Molano","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jgar.2019.08.010_bib0350","first-page":"262","article-title":"Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from abacavir\/lamivudine\/dolutegravir to lamivudine plus dolutegravir","volume":"41","author":"Lanzafame","year":"2018","journal-title":"New Microbiol"},{"key":"10.1016\/j.jgar.2019.08.010_bib0355","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2019.08.010_bib0360","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(17)30053-X","article-title":"Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study","volume":"4","author":"O\u2019Connor","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2019.08.010_bib0365","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/QAI.0b013e3181f2ac87","article-title":"Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level","volume":"55","author":"Lima","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"March","key":"10.1016\/j.jgar.2019.08.010_bib0370","article-title":"Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication","author":"Borghetti","year":"2018","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2019.08.010_bib0375","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkx233","article-title":"HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study","volume":"72","author":"Charpentier","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.08.010_bib0380","series-title":"11th Italian Conference on AIDS and Retroviruses (ICAR)","article-title":"Simplification to high-genetic-barrier 2DR in PLWH harbouring 4-class drug-resistant HIV-1 enrolled in the PRESTIGIO Registry","author":"Canetti","year":"2019"},{"key":"10.1016\/j.jgar.2019.08.010_bib0385","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa012035","article-title":"Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients","volume":"346","author":"Cote","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2019.08.010_bib0390","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1468-1293.2005.00325.x","article-title":"Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone","volume":"6","author":"Jones","year":"2005","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2019.08.010_bib0395","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00126334-200001010-00005","article-title":"Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection","volume":"23","author":"Mulligan","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2019.08.010_bib0400","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2019.08.010_bib0405","series-title":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance. Web Annex F","author":"World Health Organization (WHO)","year":"2018"},{"key":"10.1016\/j.jgar.2019.08.010_bib0410","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","article-title":"Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review","volume":"20","author":"Brown","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2019.08.010_bib0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193679","article-title":"Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection","volume":"13","author":"Vlot","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2019.08.010_bib0420","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QAI.0b013e3181adce44","article-title":"Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen","volume":"51","author":"Brown","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2019.08.010_bib0425","first-page":"385","article-title":"HIV and bone metabolism","volume":"11","author":"Ofotokun","year":"2011","journal-title":"Discov Med"},{"key":"10.1016\/j.jgar.2019.08.010_bib0430","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2019.08.010_bib0435","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir\u2013lamivudine versus tenofovir\u2013emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.08.010_bib0440","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/QAD.0000000000001725","article-title":"Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health","volume":"32","author":"McComsey","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2019.08.010_bib0445","series-title":"11th Italian Conference on AIDS and Retroviruses (ICAR)","article-title":"Changes in bone mineral density switching from tenofovir disoproxil fumarate: a comparison between lamivudine plus dolutegravir versus FTC\/TAF plus an integrase inhibitor","author":"Ciccullo","year":"2019"},{"key":"10.1016\/j.jgar.2019.08.010_bib0450","first-page":"757","article-title":"Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention","volume":"5","author":"Millan","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jgar.2019.08.010_bib0455","series-title":"11th Italian Conference on AIDS and Retroviruses (ICAR)","article-title":"Dolutegravir safety in a real-life setting: results from the SCOLTA cohort","author":"Madeddu","year":"2019"},{"key":"10.1016\/j.jgar.2019.08.010_bib0460","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25227","article-title":"Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort","volume":"22","author":"Mondi","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jgar.2019.08.010_bib0465","series-title":"11th Italian Conference on AIDS and Retroviruses (ICAR)","article-title":"Comparative neuropsychiatric toxicity profile of dolutegravir-based versus efavirenz-based versus other recommended first-line antiretroviral therapies (ART): data from ICONA Foundation study cohort","author":"Mondi","year":"2019"},{"key":"10.1016\/j.jgar.2019.08.010_bib0470","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJMoa1905230","article-title":"Neural-tube defects and antiretroviral treatment regimens in Botswana","volume":"381","author":"Zash","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519302085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519302085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:54:05Z","timestamp":1761990845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716519302085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":94,"alternative-id":["S2213716519302085"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2019.08.010","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-na\u00efve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2019.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}